Biosimilars Market

Sandoz (US) and Pfizer (US) are Leading Players in the Biosimilars Market

The global biosimilars market size is expected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. The growth in this market is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness.

The prominent players operating in the global biosimilars market include Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), Fresenius Kabi AG (Germany),  Boehringer Ingelheim (Germany), Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddys Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany).

To know about the assumptions considered for the study download the pdf brochure

The players in this market are mainly focused on product launches/approvals, expansion, collaborations, partnerships, and acquisitions to develop and expand their market presence between 2017 and 2020.

Sandoz (US) is the US leader in the biosimilars market in 2018. The company has a strong portfolio of affordable and high-quality generic medicines and provides differentiated products & standard generics to its customers. The company recorded positive growth in its revenue in 2018, as compared to that of 2017. Moreover, in 2018, the company generated 52.6% of its total revenue from Europe. The company focuses on organic and inorganic growth, such as collaboration, and product launches/product approval, to strengthen its position in the market. For instance, in 2019, the company entered into a collaboration with Polpharma Biologics to commercialize a proposed biosimilar to natalizumab for relapsing-remitting multiple sclerosis (RRMS).

Pfizer (US) is one of the leading players in the biosimilars market. The company operates through three business segments; namely, Global Innovative Pharmaceutical (GIP), Global Vaccines, Oncology, and Consumer Healthcare (VOC), and Global Established Pharmaceutical (GEP). The company majorly focuses on inorganic and organic strategies such as acquisitions and product launches/approvals. For instance, in 2019, the company received approval from the US FDA for the treatment of multiple inflammatory conditions. Such development strengthens the position of the company in the market.

Related Reports:

Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

Contact:
Mr. Sanjay Gupta
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
PH 7582
RI Published ON
3/24/2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Biosimilars Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved